
Access & Affordability
© 2021 Teva Respiratory, LLC. CIQ-41277 03/2021
Limitations of Use: CINQAIR is not indicated for:
The mechanism of CINQAIR action in asthma has not been definitively established.1
Learn more about how CINQAIR works:
View the mechanism of actionLearn about the pharmacologic profile of CINQAIR:
Review data for the reduction of blood eosinophilsSevere asthma that is inadequately controlled despite standard of care (medium-high dose ICSs with LABAs)1-3
EOS=eosinophils; FEV1=forced expiratory volume in one second; ICSs=inhaled corticosteroids; IL-5=interleukin-5; LABAs=long-acting beta agonists; OCSs=oral (systemic) corticosteroids; SABA=short-acting beta agonist.
*Blood EOS ≥400/mcL represents the patient population in CINQAIR clinical trials I, II, and III.1
REFERENCES: 1. CINQAIR Prescribing Information. West Chester, PA. Teva Respiratory, LLC. 2. National Asthma Education and Prevention Program (NAEPP). Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma–Full Report 2007. Bethesda, MD: US Department of Health and Human Services, National Institutes of Health, National Heart, Lung, and Blood Institute; August 2007. 3. Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention, 2016. www.ginasthma.org. Accessed December 14, 2020. 4. Castro M, Zangrilli J, Wechsler ME, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med. 2015;3(5):355-366.